Small molecule CDMO Cambrex is to spend $3.6 million to increase flexible drug substance manufacturing capacity by 6 m³ (25%) at Karlskoga, Sweden, in response to growing demand for commercial-scale API manufacturing. Engineering work has already commenced and should be completed by November.

Two of the major global pharmaceutical CDMOs, Lonza and Alcami, have announced the appointments of new CEOs in early June. There have also been changes in senior positions at Corden Pharma and, imminently, at Cambrex.